Blocking fatty ceramides could stop acute kidney injury—and possibly revolutionize mitochondrial disease treatment.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...

Chronic kidney disease is a gradual, irreversible loss of kidney function caused by diabetes, hypertension, or ageing. It ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

If the drug works in people, it could prevent kidney injury in high-risk populations, or potentially even treat other ...

Background: Among patients with focal segmental glomerulosclerosis (FSGS), proteinuria and kidney function decline may be ...

The Liberation From Acute Dialysis (LIBERATE-D) randomized clinical trial tested the value of a conservative vs conventional hemodialysis strategy on recovery of kidney function in stable patients ...

A research team at the University of Pittsburgh, led by Dr. Anne Robertson and PhD candidate Fatemeh Azari, discovered that the bladder does not simply inflate like a balloon when it fills. Instead, ...

HOUSTON -- Two commonly used kidney function tests had a large degree of disagreement and were linked with serious health ...

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...

Your kidneys work around the clock filtering about 200 quarts of blood daily, removing waste products, balancing electrolytes ...